How I Choose Among Osteoporosis Treatments
  • CME
  • CE

I answer common questions on estrogen, anabolic agents, and steroids in the treatment of osteoporosis.
Nancy E. Lane, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: May 25, 2021 Expiration: May 24, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement recently released guideline recommendations for screening for osteoporosis and next steps in management
  • Describe the various treatment modalities for osteoporosis including mechanism of action, efficacy, and safety

Acknowledgements

In collaboration with Nurse Practitioners in Women's Health
Supported by educational funding provided by
Amgen

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Nancy E. Lane, MD

Distinguished Professor of Medicine and Rheumatology
Division of Rheumatology
Department of Medicine
UC Davis Health
Sacramento, California

Nancy E. Lane, MD, has disclosed that she has received consulting fees and fees for non-CME/CE services from Amgen and Mallinckrodt.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for primary care providers (MD, DO, and NP) who treat adult women at risk for osteoporosis, including family medicine, internal medicine, and OB/GYN.

Goal

The goal of this activity is to improve the competence of primary care providers, including physicians, nurse practitioners, and other members of the healthcare team, in screening for, diagnosing, and treating osteoporosis to reduce osteoporotic fractures in high-risk individuals.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 25, 2021, through May 24, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Dr Derek LeRoith discusses the role of fixed-ratio combination basal insulin and GLP-1 RA treatment in older adults with type 2 diabetes, from Clinical Care Options (CCO).

Derek LeRoith, MD, PhD Released: March 31, 2022

Expert commentary on the use of diabetes technologies in pediatric patients, from Jennifer Sherr, MD, PhD, and Clinical Care Options (CCO)

Jennifer Sherr, MD, PhD Released: January 14, 2022

Listen to expert insights from Martin C. Mahoney, MD, PhD, on new data for vaccine-preventable diseases presented at the IDWeek meeting, including pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: December 6, 2021

Clinical Care Options (CCO): Dr. Paul Auwaerter discusses the latest pneumococcal vaccine data and the impact on his practice, presented at IDWeek 2021

Paul G. Auwaerter, MD Released: November 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings